ENO2

Across TCGA pan-cancer cohorts, ENO2 RNA is linked to patient survival in 29 of 34 cancer types, making it the most broadly survival-associated ENO2 data layer compared with 7 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ENO2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ENO2 expression acts as an unfavorable survival marker, although some lineages such as LGG and OV show a favorable association.

MESO, KIRP, and KICH are the cancer types where ENO2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.255	0.482	<.001	113	view →
KIRP	DFS	Median	All	0.787	0.920	<.001	91	view →
KICH	DFS	Median	III,IV	0.409	1.000	.002	73	view →
THCA	DFS	Quartile	IV	0.644	1.000	<.001	48	view →
COAD	DFS	Median	All	0.418	0.593	.003	41	view →
LGG	OS	Median	All	0.937	0.852	<.001	36	view →
LIHC	OS	Median	All	0.611	0.761	<.001	31	view →
UVM	DFS	Median	II,III,IV	0.339	0.597	.009	23	view →
CESC	DFS	Tertile	All	0.765	0.867	.013	18	view →
OV	DFS	Median	All	0.590	0.490	.007	18	view →
ACC	DFS	Quartile	All	0.226	0.707	.001	16	view →
KIRC	DFS	Median	II,III,IV	0.448	0.599	.010	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 29 lineages.

ENO2–MESO (DFS)

Open the MESO breakdown →